Increased tachykinin NK1 receptor immunoreactivity in the prefrontal cortex in schizophrenia

被引:26
作者
Tooney, PA [1 ]
Crawter, VC
Chahl, LA
机构
[1] Univ Newcastle, Fac Med & Hlth Sci, Sch Biomed Sci, Callaghan, NSW 2308, Australia
[2] Neurosci Inst Schizophrenia & Allied Disorders, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
schizophrenia; tachykinin; NK1; receptor; prefrontal cortex; human; immunohistochemistry;
D O I
10.1016/S0006-3223(00)01068-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Changes in levels of substance P and substance P-binding sites have been implicated in schizophrenia . However, no studies have used receptor-specific antibodies to directly investigate the substance P (neurokinin 1) receptor in schizophrenia. Methods: We used an antibody directed against the human neurokinin-1 receptor to compare the distribution of neurokinin-1 receptors in the prefrontal cortices from six subjects with schizophrenia and six control subjects, matched for age, gender, and postmortem interval. Results: In control tissue, dots of neurokinin-1 receptor immunoreactivity were observed in layer I to upper/mid layer III only. In contrast, dots of neurokinin-1 receptor immunoreactivity were observed in all layers of the prefrontal cortex in subjects with schizophrenia, and the density of dots was significantly greater than in control subjects. Conclusions: This is the first report of increased neurokinin-1 receptor immunoreactivity in the prefrontal cortex in subjects with schizophrenia. These changes may have implications for understanding the pathophysiology of the prefrontal cortex in schizophrenia and for the treatment of this disorder.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 16 条
[1]   EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTIC TREATMENT ON PROTACHYKININ MESSENGER-RNA LEVELS IN THE STRIATUM OF THE RAT [J].
ANGULO, JA ;
CADET, JL ;
MCEWEN, BS .
NEUROSCIENCE LETTERS, 1990, 113 (02) :217-221
[2]  
Bohm SK, 1997, J BIOL CHEM, V272, P2363
[3]   Substance P (NK1) receptors in the cingulate carter in unipolar and bipolar mood disorder and schizophrenia [J].
Burnet, PWJ ;
Harrison, PJ .
BIOLOGICAL PSYCHIATRY, 2000, 47 (01) :80-83
[4]   The neuropathology of schizophrenia - A critical review of the data and their interpretation [J].
Harrison, PJ .
BRAIN, 1999, 122 :593-624
[5]  
HUMPEL C, 1990, SYNAPSE, V6, P1
[6]   BIOCHEMICAL-CHARACTERIZATION OF 2 DIFFERENT FORMS OF THE SUBSTANCE-P RECEPTOR IN RAT SUBMAXILLARY-GLAND [J].
KAGE, R ;
LEEMAN, SE ;
BOYD, ND .
JOURNAL OF NEUROCHEMISTRY, 1993, 60 (01) :347-351
[7]   Distinct mechanism for antidepressant activity by blockade of central substance P receptors [J].
Kramer, MS ;
Cutler, N ;
Feighner, J ;
Shrivastava, R ;
Carman, J ;
Sramek, JJ ;
Reines, SA ;
Liu, GH ;
Snavely, D ;
Wyatt-Knowles, E ;
Hale, JJ ;
Mills, SG ;
MacCoss, M ;
Swain, CJ ;
Harrison, T ;
Hill, RG ;
Hefti, F ;
Scolnick, EM ;
Cascieri, MA ;
Chicchi, GG ;
Sadowski, S ;
Williams, AR ;
Hewson, L ;
Smith, D ;
Carlson, EJ ;
Hargreaves, RJ ;
Rupniak, NMJ .
SCIENCE, 1998, 281 (5383) :1640-1645
[8]   A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization [J].
Li, HZ ;
Leeman, SE ;
Slack, BE ;
Hauser, G ;
Saltsman, WS ;
Krause, JE ;
Blusztajn, JK ;
Boyd, ND .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9475-9480
[9]   Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study [J].
Mileusnic, D ;
Lee, JM ;
Magnuson, DJ ;
Hejna, MJ ;
Krause, JE ;
Lorens, JB ;
Lorens, SA .
NEUROSCIENCE, 1999, 89 (04) :1269-1290
[10]  
PATACCHINI R, 1995, ARCH INT PHARMACOD T, V329, P161